Homer Pearce Aug 09, 2007 Premium Save for later Kylin Therapeutics this week said it has appointed Homer Pearce to its board of directors. Pearce was previously vice president of cancer research and clinical investigation at Eli Lilly. He holds a PhD in chemistry from Harvard University. Filed under Gene Silencing/Gene Editing RNAi Breaking News In Brief This Week: Pacific Biosciences, Invitae, Grail, Mainz Biomed, Molzym, More GenomeWeb Top 40 Down 5 Percent in June, Tracking Broader Market Decline Euformatics Wins €350K European Grant to Develop NGS Workflows for Cancer, Rare Disease Dx PreventionGenetics Nabs FDA Approval for Obesity Drug Companion Diagnostic Settlement of Micronesia Emerges from Ancient DNA Analysis The Scan Alzheimer's Risk Gene Among Women CNN reports that researchers have found that variants in MGMT contribute to Alzheimer's disease risk among women but not men. Still Hanging Around The Guardian writes that persistent pockets of SARS-CoV-2 in the body could contribute to long COVID. Through a Little Spit Enteric viruses like norovirus may also be transmitted through saliva, not just the fecal-oral route, according to New Scientist. Nature Papers Present Method to Detect Full Transcriptome, Viruses Infecting Asgard Archaea, More In Nature this week: VASA-seq approach to detect full transcriptome, analysis of viruses infecting Asgard archaea, and more. What's Popular? ERS Genomics Licenses CRISPR Tech to Swiss Firm Cytosurge